Clinical trial data show that while fat mass accounts for the majority of weight loss, some lean mass reduction also occurs, which could potentially affect muscle function
Based on current clinical evidence, the rough ordering from largest to smallest weight-loss effect is: Tirzepatide highest average weight loss Semaglutide significant weight loss Tesamorelin moderate weight loss, primarily through visceral fat reduction AOD-9604 primarily body composition effects MOTS-c primarily metabolic and energy effects rather than pure weight reduction AOD-9604 and MOTS-c are generally not considered replacements for GLP-1 medications in patients seeking substantial weight reduction
People are shifting to every other week dosing to reduce the monthly expenses of semaglutide, reduce the severity of side effects, and maintain weight loss and metabolic benefits of semaglutide in the maintenance phase
Summary: Ozempic (semaglutide) is not recognised as causing photosensitivity according to UK regulatory guidance, clinical trials, or the Summary of Product Characteristics
Further randomized controlled trials and long-term observational studies are needed to validate its efficacy and safety profile
